FDA grants ODD status to Zai Lab’s lung cancer treatment
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).
Macau Business16h
Corero Network Security Enhances UK Dedicated Servers’ DDoS Defense with High-Performance Upgrade
UK Dedicated Servers Strengthens Partnership with Corero as First EMEA Adopter of New Adaptive NTD3400 DDoS Solution. MARLBOROUGH, Mass., Jan. /PRNewswire/ — Corero Net ...
Zai Lab Gets FDA Orphan Drug Designation For ZL-1310 To Treat Small Cell Lung Cancer
Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...
Le Lézard23h
IMCAS 2025: Galderma's Broad Presence and New Data on Recently Launched Products Restylane® SHAYPEtm and Relfydess® Reaffirm Its Category Leadership
Galderma will present the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025 on January 30 ? February 1 in Paris, ...